As of last quarter Aridol accounted for just over 40% of total revenue (400 out of 962). However Aridol's real COGS( COGS- Sales & marketing) will be virtually nothing compared to what goes into Bronchitol, and at this stage it's the only part of the business that could turn a Net profit.
Close to 40% of Aridol sales come from the US, however keeping a clean sheet with the FDA, and selling in the US is of utmost importance- especially when you seeking an apporval for another product that's manufactured/ or "packed" in the same factory/location. Selling Aridol in the US also raises the awareness of the company's profile/ and promotes Bronchitol. The so called "packing issues" with Aridol could also cause through back issues with the likes of Europe, and delays on a real clarification are starting to become concerning.
The company was notified of FDA import restriction back in May, and brushed it off as an issue with" a third party contract packer"... it's now over 4 months later and there's been no real clarification from the Company. So this leaves the market wondering if perhaps its more of a "Manufacturing issue"... That's my interpretation anyway.
Also, at the time of the important restriction, it was said PXS had 3 months supply of Aridol already on hand in the US...that supply has now ran out.
PXS Price at posting:
12.0¢ Sentiment: None Disclosure: Not Held
